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Contact hypersensitivity (CHS) responses require the participation ofT cells, along with a variety 
of cytokines and adhesion molecules. In the classical CHS, antigen-specific T cells are recruited 
to a site of antigenic challenge, where they react with antigen, release cytokines, and attract 
other inflammatory cells. In the mouse model of CHS, this reaction is elicited in sensitized mice 
by application of the immunogen 4-7 d after immunization. The reaction peaks at 24 h, is slightly 
reduced by 48 h, and can return to normal by 72 h. This is in spite of the fact that some antigen 
is still present at the site of challenge. Here we examined the hypothesis that locally produced 
interleukin 10 (IL-10) regulates the duration of the response. Our data show that IL-10 protein 
peaked 10-14 h after antigenic challenge and returned to background by 24 h. The production 
of IL-10 protein corresponded with,  and followed IL-IO mRNA transcription as detected by 
reverse transcriptase-polymerase chain reaction. During peak IL-10 production after antigenic 
challenge, it was not possible to transfer CHS with immune lymphoid cells, unless neutralizing 
antibody to IL-10 was given first.  Additionally, when sensitized mice were given neutralizing 
anti-IL-10 antibody at the time of antigenic challenge, the duration of CHS was prolonged well 
beyond the natural course of the response. Finally, we demonstrate that rlL-10, when injected 
into the skin before antigenic challenge, prevented the elicitation of CHS in previously sensitized 
mice. Taken together, our data show an important role for IL-IO in the natural regulation of 
CHS responses in vivo. 
T 
he control of the magnitude and duration of immune 
responses has been attributed to several factors.  These 
include the retention/release of antigen (1), induction of toler- 
ance (2, 3), activation of suppressor cells (4, 5), and the re- 
lease of inhibitory cytokines (6, 7). The classic experimental 
system for inflammatory cell-mediated immunity in skin is 
contact  hypersensitivity (CHS) 1 (1-18).  This response re- 
quires the participation  of CD4 + and CD8 + T  cells (13, 
14), as well as other inflammatory cells (8-10).  Numerous 
cytokines (6, 7) have been shown to be involved, as well as 
adhesion molecules (9-11) that are committed to helping cells 
migrate to the skin. In the typical reaction, application of 
the immunizing agent to skin results in the activation of 
antigen-specific T cells in the draining lymph nodes. Subse- 
quent to the initial sensitizing dose (typically 4-7 d), the reap- 
plication of the same antigen to skin results in the influx of 
antigen-specific T  cells, which react to the antigen locally, 
1 Abbreviations used in this paper: CHS, contact hypersensitivity;  DTH, 
delayed type hypersensitivity; G3PDH, glyceraldehyde  3-phosphate 
dehydrogenase;  TNBS, 2,4,6 trinitrobenzene  sulfonic  acid; TNCB, 2,4,6- 
trinitro-  1  -chlorobenzene. 
release cytokines, and attract other inflammatory cells (mac- 
rophages and PMNs)  to the site. The resultant edema can 
then be measured as a record of the immune response. The 
reaction proceeds in an antigen-specific manner (8) and can 
be passively  transferred to naive mice with T  cells (9,  10). 
The response typically peaks at 24 h, with some reduction 
at 48 h, and by 72 h  the area can return to normal size in 
spite of the continued presence of antigen. Thus, it has been 
suggested that the magnitude and duration of the response 
is controlled locally by the production of "factors" that con- 
trol the duration of the response (6,  19). 
Recent studies have shown that a number of cytokines are 
produced in the skin after the application of antigen for CHS 
(6, 7). These include TNF-c~, IFN-3', GM-CSF, IL-lot, IL- 
1~, and IL-IO. Data indicate that an interesting temporal rela- 
tionship exists between the upregulation of the mRNA for 
these molecules and the elicitation of the CHS reaction (6). 
We were interested in examining those cytokines that might 
be involved in downregulating the response. IL-10 is a mul- 
tifunctional molecule produced by a number of cell types 
(19-37). Besides being a growth factor for several cell types 
(20, 24, 25),  a major function of this cytokine is the inhibi- 
tion of Thl cell function. These are the cells shown to be 
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reactions (32-34).  Therefore, we tested the hypothesis that 
production of IL-IO at sites of antigenic challenge regulates 
the T  cell responses in CHS.  Our results demonstrate  that 
IL-IO is involved in  the  natural  control  of CHS responses 
in  skin. 
Materials  and Methods 
Mice.  BALB/cByJ mice were purchased from The Jackson Lab- 
oratory (Bar Harbor, ME). In all in vivo experiments, groups con- 
sisted of five or more animals.  Experiments were repeated at least 
three times with similar results before they were reported. 
Antigens, Antibodies, and Reagents.  2,4,6-trinitro-l-chloroben- 
zene  (TNCB)  was  purchased  from  Eastern  Chemical  Co. 
(Smithtown, NY). 2,4,6 trinitrobenzene sulfonic acid (TNBS) was 
purchased from Sigma Chemical Co. (St. Louis,  MO). The neu- 
tralizing rat antibodies to mouse IL-10,  JES5.2A5  (IgG1) and SXC-1 
(IgM) (24,  36) were kindly provided by DNAX Inc. (Palo Alto, 
CA). For ELISA, antibodies were prepared from culture superna- 
tants by passage over a protein G-Sepharose column. Antibodies 
for in vivo experiments were prepared as ascites fluid in SCID mice. 
Antibodies were quantitated using a sandwich ELISA for rat IgG1 
and IgM. Recombinant murine IL-10 (rlL-10) was purchased from 
Genzyme Corp.  (Cambridge, MA). 
Contact Hypersensitivity~.  BALB/c mice were painted on shaved 
abdominal skin with 100 #1 of 2% TNCB dissolved in acetone/olive 
oil 3:1 (vehicle).  After 4-5 d, mice were killed and single cell sus- 
pensions were made from draining lymph nodes and spleens. For 
adoptive transfer,  5  x  107 cells were injected intravenously via the 
retro-orbital plexus into syngeneic recipients (total volume, 200 
/zl). Mice were ear challenged with 1% TNCB (acetone/olive oil, 
3:1) and CHS was measured at 24 h as the difference between the 
right ear (challenged)  and the left ear (unchallenged).  In some cases, 
measurements were made at 24,  48,  72,  and 96 h. All measure- 
ments were done with an engineer's micrometer by an investigator 
who did not know the identity of the groups. Background values 
(Bkg) were determined by the difference  in ear swelling between 
the antigen challenged and unchallenged ears of naive mice. To de- 
termine the effect of rlL-10 injection,  mice sensitized 4 d earlier 
with 2% TNCB were challenged in the right footpad with 0.033 
ml of 10 mM TNBS and in the left footpad with 0.033 ml of PBS 
2 h  after injection  of rlL-10. 
Tissue Extraction and 11_,10 ELISA.  At various times after ap- 
plication of TNCB, ears were excised, weighed, and each ear was 
added to a 1.5-ml microcentrifuge tube. To each sample was added 
0.5  ml of 0.1%  Tween 20 in PBS and samples were ground for 
3-5 min with a pellet pestle (Kontes Scientific  Glassware/Instru- 
ments, Vineland, NJ) attached to a three-eighths-inch cordless elec- 
tric drill (Sears Roebuck and Co., Chicago, IL). Samples were then 
quick  frozen  in  liquid  N2,  thawed  in  a  37~  water bath,  and 
ground again for 3-5 rain.  Samples  were sonicated for 15 s and 
then centrifuged for 5 min at 13,000g. Supernatants were removed 
for IL-IO determination. 
ILl0 in ear tissue was quantitated using a sandwich ELISA de- 
veloped with the two anti-IL-10 mAbs. 96-weU ELISA immunoplates 
(Polysorb; Nunc, Roskilde, Denmark) were coated with 2 #g/ml 
purified  JES5.2A5  mAb  diluted  in  coating  buffer  (0.1  M 
NaHCO3/0.1  M  Na~CO3).  After overnight incubation  at 4~ 
wells were blocked with 1% BSA in PBS for 2 h at room tempera- 
ture.  Plates were then washed three times with PBS containing 
0.1% Tween-20 (PBS/Tween) and the rlL-10 standard or test samples 
were added (100/zl/well).  Standard and unknowns were diluted 
in PBS/Tween containing 10% BSA. Plates were incubated over- 
night at 4~  wells were washed four times with PBS/Tween, and 
100 #l/well of biotinylated mAb SXC-1 (1/zg/ml) was added for 
45 min at room temperature. Wells were washed at least six times, 
followed by the addition of 100 #1 of 1:500 avidin-alkaline phos- 
phatase (Sigma Chemical Co.) for 30 min at room temperature. 
Wells were washed at least eight times with PBS/Tween and 100 
#1 of p-nitrophenyl phosphate (Zymed Laboratories, Inc., South 
San Francisco,  CA) was added. Upon color development, the plate 
was analyzed on an ELISA plate reader at OD 405 nm. The ELISA 
did not react with IL-2, IL-4,  TNF-ct,  Iblot, or IFN-% 
RTPCRforlLIO.  At various times after application of TNCB 
or vehicle, ears were excised.  They were then washed once with 
PBS  and  stored  at  -80~  Total  RNA  was  extracted  using 
guanidium thiocyanate as described by Chomczynski (38). Samples 
were treated with KNase-ffee DNase I at 37~  for 30 min, the 
KNA  reprecipitated,  and  KNA  concentrations  determined  by 
OD260. All samples were brought to 5 ng//zl and samples tested 
for DNA contamination by 40 cycles of PCK using the glyceralde- 
hyde 3-phosphate dehydrogenase (G3PDH) primers, cDNA syn- 
thesis was then performed by the instructions  on a KNA PCK 
kit  (model no.  N808-0017;  Perkin-Elmer Cetus,  Norwalk,  CT) 
using total RNA and the oligo d(T)16 primer provided with the 
kit. The RT reaction used M-MuLV reverse transcriptase and the 
thermal program was run at 42~  for 1 h followed by 95~  for 
5 min. cDNA products were stored at  -80~  until used.  Primers 
were  synthesized  by  Keystone Laboratories  (Menlo  Park,  CA) 
and were: G3PDH, 5'-ATCTTCTTGTGCAGTGCCAGC-Y and 
5'-TATTTCTCGTGGTTCACACCC-Y, giving a 450-bp product; 
ILl0, 5'-CCCAGAAATCAAGGAGCATTTG-Y and 5'-CATGTA- 
TGCTTCTATGCAGTTG-Y, giving a 209-bp product as described 
(19). 
PCR  conditions  were  optimized  such  that  only the  desired 
product was produced.  Cycle conditions were 95~  for I min, 55~ 
for 1.5 rain, and 72~  for 2 min. This was repeated for 40 cycles 
with the G3PDH primers and for 45 cycles with the IL-10 primers 
and  reaction  mixtures  contained  ot[32p]dCTP  (1  #CiAample). 
Samples were then run on 2% agarose gels and bands visualized 
using ethidium bromide.  The observed bands were cut out and 
counted using a beta counter (model LS-5000 CE; Beckman In- 
struments, Fullerton, CA). Counts per minute values for G3PDH 
were used for comparison to II,-10. Values are expressed as the ratio 
of IL-10 cpm to G3PDH cpm, and each point represents the av- 
erage of two to five samples.  Experiments were repeated at least 
three times. 
Treatment of Mice with Anti-ILlO.  Normal mice were treated 
with 0.5  mg of anti-IL-10  24 h before application of antigen to 
skin. They were then treated with 0.5 mg of antibody intravenously 
at the time of antigen application. In some experiments where the 
effect of neutralizing IL-10 was determined by measuring on con- 
secutive days after challenge, 0.5 mg of anti-IL-10 was given daily. 
Control antibody was 0.5  rag/mouse of rat IgG. 
Statistics.  Significant differences between groups was evaluated 
using a two-tailed Student's  t test (p <0.05). 
Results 
Detection of IL-IO  in Skin.  We  wanted  to  examine the 
production of IL-10 protein in the skin of mice treated with 
TNCB. Thus, we developed an ELISA to detect IL-10 using 
two mAb specific for the protein. Data in Fig.  1 show that 
there was a baseline level of IL-10 detectable in skin (normal) 
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Figure  1.  The amount of IL-10 
protein was detected in skin using 
an  ELISA. Normal  BALB/cByJ 
mice were painted with 1% TNCB 
and  the  ears excised  at  various 
times. Experimental groups include 
TNCB  only,  TNCB/anti-IL-10 
(JES5.2AS), and vehicle only (3:1 
acetone/olive  oil). After excision,  the 
ears were weighed, protein was ex- 
tracted, and the amount of IL-10  was 
determined  by  comparison  to  a 
known standard of rlL-10. Values are 
expressed as nanograms of IL-10 per 
gram of tissue. Each value represents 
the mean of three to five individual 
samples. 
that remained unchanged for the first 8 h after application 
of TNCB. The amount of the protein increased at 10 h, reached 
maximum level at  14 h,  and fell back to normal by 24 h. 
Skin treated with vehicle alone did not upregulate the amount 
of IL-10. We also examined the level of IL-10 protein in painted 
skin after treatment with neutralizing  antibody to IL-10 (SXC- 
1).  In this case, there was a barely detectable level of protein 
suggesting that we had neutralized (or at least bound) virtu- 
ally all IL-10. Note that treatment with JESS-2A5.11 or SXC-1 
resulted in nearly identical data,  as  noted by others  (35). 
In Fig.  2  we  examined the production  of mRNA  after 
TNCB  application.  These data  show  that  by 8-10 h  after 
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Figure 2.  The  amount  of  II.-10 
mRNA was detected in skin by using 
ILT-PCR.  Normal  BALB/cByJ mice 
were painted with 2% TNCB and the 
ears  excised  at  various  times.  Ex- 
perimental groups include TNCB only, 
TNCB/c~-IL-10 (SXC-1), and vehicle 
only (3:1 acetone/olive oil). After exci- 
sion, ears were weighed, mRNA was 
extracted, and RT-PCR was performed 
in  the  presence  of  ot[32p]dCTP. 
Samples were run on 2% agarose gels, 
bands  were  cut out,  and counts per 
minute determined. Values  are expressed 
as the ratio of counts per minute for 
IL-10 product  (209 bp)  to  G3PDH 
product (450 bp). Each point represents 
the average of two to five individual 
samples. 
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rapidly upregulated,  peaking at 12-14 h  and falling to base- 
line levels by 18 h. Treatment with anti-IL-10 resulted in less 
IL-10 mRNA,  however, caution must be exercised since this 
was not a quantitative  PCR.  The pattern of IL-10 mRNA 
production  in anti-IL-10-treated  mice was nearly identical 
to that for untreated mice. Vehicle alone does not upregulate 
IL-10 mRNA.  Thus, the mRNA correlates with the produc- 
tion  and  upregulation  of IL-10  protein  by  application  of 
TNCB.  These data are in agreement with previously pub- 
lished results showing IL-10 mRNA  in treated skin by RT- 
PCR  (19), however, our data show that a constitutive level 
of mRNA  and protein were present.  Note that the levels of 
IL-10 protein  and IL-IO  mRNA  are the  same whether  the 
mice are naive or presensitized to TNCB  (data not shown). 
Anti-IL-lO Prolongs the CHS Response.  If IL-10 is involved 
in controlling the duration of the CHS response, we should 
be able to alter the response by neutralizing  this  cytokine. 
Naive mice were given anti-IL-10 (JES5.2A5) or control IgG 
along with TNCB immune cells before ear challenge. Ears 
were challenged with TNCB  and responses were measured 
on three consecutive days. Results in Fig. 3 A  show that the 
normal  response was maximal  at  24  h,  50%  less at 48  h, 
and near background by 72 h. When anti-IL-10 was given, 
however, the CHS response continued through the 72-h time 
point at a level comparable with the maximal 24-h response. 
In Fig.  3  B  a  similar experiment  was performed with  the 
SXC-1 anti-IL-10 but instead of cell transfer, treatments were 
done in previously sensitized mice, and measurements were 
taken  on  four  consecutive  days.  In  this  case,  anti-IL-10 
prolonged  the response for 94 h.  Therefore,  we concluded 
that the presence of this cytokine was important for the down- 
regulation  of the  CHS  response. 
CHS Was Not Transferable during Peak IL-IO Production.  In 
Fig.  1 we demonstrated  that  IL-10 was increased between 
8 and 14 h  after antigenic challenge. To further test our hy- 
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Figure  3.  Anti-IL-10  prolongs the CHS response. 
(A) Mice were treated with anti-IL-10  or a control rat 
IgG to determine  the effect  on the CHS response. Naive 
BALB/cByJ mice received  no treatment (Immune), 0.5 
mg JES5.2A (2/15), or 0.5 mg control rat IgG (Con- 
troO and received 5 x  107 TNCB immune spleen and 
lymph node cells, and were ear challenged (right ear 
only) with 1% TNCB. Measurements were taken at 
24, 48, and 72 h. (B) Naive BALB/c mice were sensi- 
tized by topical application of 2% TNCB. They were 
given 0.5 mg SXC-1 or 0.5 mg of rat Ig (Control) and 
were ear challenged with 1% TNCB. Measurements 
were taken at 24, 48, 72, and 96 h. Background values 
are included to demonstrate how values normally re- 
turn  to background  levels on  successive days. (*) 
Statistically significant difference from immune con- 
trol (Immune). 
1600  IL-10 and Contact Hypersensitivity pothesis that IL-10 was important for downregulation of the 
response, we attempted to transfer CHSjust before, during, 
and after peak IL-10 production in TNCB-sensitized  skin. 
To do this, naive mice were challenged at various times be- 
fore adoptive transfer of TNCB-immune  ceils,  and the re- 
sponse measured 24 h  after challenge. Data in Fig. 4  show 
that when cells were transferred during peak IL-10 produc- 
tion (12 h) it was not possible to transfer the CHS response. 
It is interesting to note that when cells are transferred just 
before peak IL-10 (8 h) or after IL-10 levels return to normal 
(20 h), it is still not possible to transfer CHS.  At all time 
points, however, the barrier to transfer was overcome by prior 
injection of the neutralizing antibody to IL-10 (SXC-1), sug- 
gesting  that  IL-10 was  critical to preventing CHS transfer 
at  these  time points. 
1L-10 Prevented the Elicitation of Immunity.  To further test 
the hypothesis that IL-10 is important  in the regulation of 
CHS,  we attempted to modulate  the response by injecting 
the cytokine in vivo. Mice were sensitized to TNCB and 5 d 
later challenged with TNBS by injection in the footpad. One 
group received an injection of 150 ng rlL-10 2 h before anti- 
genic challenge. This amount was chosen because it is an in- 
termediate value for IL-10 as detected in sensitized skin. Data 
in Fig.  5  show  that  pretreatment  of the mice with  rlL-10 
prevented the elicitation of immunity in previously sensitized 
mice. 
Discussion 
Control  of the  duration  and  magnitude  of immune  re- 
sponses can be attributed to a number of biological responses, 
including loss of antigen from the site (1), induction of toler- 
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Figure 4.  CHS was not transferred  during peak IL-10  production. Naive 
BALB/c mice were given control rat IgG (Immune~rat  IgG) or anti-IL-10 
(lmmune/anti-lblO) 0-ES5.2A5) at the time of ear challenge  with 1% TNCB. 
At 0, 8, 12, and 20 h, mice received 5 x  107 immune spleen and lymph 
nodes. Ear thickness was determined 24 h later. Values represent the differ- 
ence between the right ear (challenged) and the left ear (unchallenged) 
and are expressed in micrometers. A background value (25.4 #m) repre- 
sented by naive, challenged mice that did not receive immune cells was 
subtracted from each group. 
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Figure 5.  Pretreatment with rlL-10 blocks immunity. Mice were im- 
munized with 2% TNCB (Immune)  or nothing (Bkg) on shaved abdominal 
skin. 5 d later some mice received a footpad injection of 150 ng of rib10 
in the footpad 2 h before injection of 0.033 ml of 10 mM TNBS. Footpad 
thickness was measured 24 h later. Values represent the difference  between 
the right footpad (challenged) and the left footpad (unchallenged) and 
are expressed in micrometers. 
anceAuppression (2-5), and/or production of inhibitory cyto- 
kines (6,  7).  The probable existence of controlling mecha- 
nisms is well represented by the murine CHS model. In this 
response, application of sensitizing antigen to previously im- 
mune mice results in a maximal response 24 h later. By 48 h 
the response is somewhat reduced, and by 72 h the site returns 
to normal.  In  this paper we examined the hypothesis that 
IL-10 plays a role in the natural control of the duration of 
this response, and our data make a strong argument for this. 
We have shown that IL-10 protein is normally present in skin, 
and that it is upregulated after application of antigen. Treat- 
ment of mice with anti-IL-10 was sufficient to neutralize much 
of the detectable IL-10 in the skin. When IL-10 was neutral- 
ized,  the duration of the CHS was prolonged well beyond 
the natural course of the response. We further demonstrated 
that during  peak IL-10 production  at  the site of antigenic 
challenge, it was not possible to adoptively transfer CHS with 
immune cells, unless the mice were previously treated with 
neutralizing  anti-IL-10.  Additional  experimental  evidence 
demonstrated that injection of IL-10 before antigen prevented 
the elicitation of CHS in previously sensitized mice. Thus, 
we conclude that IL-10 is a very important regulator of this 
T  cell-mediated immune response. 
Recent studies  (20-37)  have demonstrated  an important 
regulatory role for IL-10 in other systems. IL-10 was origi- 
nally  described  as  a  product  of CD4 §  Th2  cells  that  in- 
hibited IL-2 and IFN-3~ production by CD4 § Thl cells (28, 
32, 36). However, it has now been shown that IL-10 is made 
by a variety of cells including B lymphocytes (20, 24), mac- 
rophages (23), keratinocytes (19), and mast cells (21). IL-10 
is a multifunctional cytokine that  has been shown to pro- 
mote  the  growth  of B  cells  (Ly-1 +)  (24),  inhibit  class  II 
MHC on monocytes (37), and function as a CTL differentia- 
tion factor (25). IL-10 exerts many of its functions through 
activity on macrophages  (and other APCs)  such as inhibi- tion of IL-1, IL-6, TNF-ot, and GM-CSF production (22). 
It has also been shown to inhibit the expression of the costimu- 
lator B7 (24), which is an important molecule for T cell acti- 
vation  (39). 
In skin, it has been shown that keratinocytes are the pre- 
dominant  source of IL-IO. Recent studies have shown that 
after application of an allergen, mRNA for IL-10 is rapidly 
upregulated (19). In fact, the inhibitory effects of UV irradi- 
ation on skin may be mediated by the release of IL-10 from 
keratinocytes (40).  We confirm and extend these studies by 
measuring the level of protein in skin. Our data show a con- 
stitutive production of the cytokine both at the mRNA and 
protein levels. The IL-10 is probably within the keratinocyte 
and not available  to other cells in the area.  Application  of 
the contact sensitizer likely causes release of the cytokine for 
the purpose of regulation, similar to the effect of UV irradia- 
tion. The constitutive levels might be present for rapid deploy- 
ment to control local, potentially harmful (if uncontrolled), 
immune  reactions  such  as CHS.  Similar  results have been 
shown for IL-1, where this cytokine is present in cells con- 
stitutively (41) and cell death or injury (apoptosis) leads to 
its release (42). Additionally, the constitutive IL-10 may func- 
tion to regulate APC function of the producing cell (keratino- 
cyte), which has been shown to play a role in CHS induction 
(15, 43). Indeed, recent evidence showing that keratinocytes 
induce hapten-specific unresponsiveness  support  this. 
CHS is a CD4 +- and CD8 +-mediated T cell reaction (13, 
14). We do not know which cell types are affected by IL-10 
in the skin.  Since IL-10 is a growth signal for CD8 § cells 
(25),  it may function  in a dual capacity by simultaneously 
inhibiting  CD4 +  Thl  cell  function  (32),  and  activating 
CD8 + cells that can regulate CHS in vivo (5).  Recent evi- 
dence showing that IL-10 is chemotactic for CD8 + cells (31) 
and that IL-10 may be a potent recruitment signal for leuko- 
cyte migration  is supportive of this idea (33).  Since IL-10 
does not act directly on T  cells (32), a possible scenario in 
the present  system is that  application  of antigen results in 
increased production  and release  of IL-10 by keratinocytes. 
The protein is then taken up by local APCs (e.g., Langerhans 
cells) that,  in turn,  inhibit further Thl cell activation (i.e., 
CHS). One recent study has shown that IL-10 inhibits the 
APC function of Langerhans ceils for Thl, but not Th2 cells 
(27). Since Langerhans  ceils are believed to be the major APCs 
in skin (12,  16, 17), these cells are an obvious site of action 
for IL-10. It is also possible that IL-10 converts skin Langer- 
hans  cells  from  immunogenic  to  tolerogenic  by  down- 
modulating B7 (24, 27). It has been suggested that one func- 
tion  of IL-10 is  to convert APCs from those that  induce 
immunity to those that induce tolerance by downregulating 
B7 on the APCs (27). These "tolerogenic" APCs could then 
serve to regulate immunity by migrating to the lymph node 
and inducing anergy. An additional (but not mutually exclu- 
sive) mechanism might involve the recently observed effect 
of IL-10 on mouse macrophages.  It was observed that IL-10 
causes these cells to round up and become less adherent  in 
culture (32). In TNCB skin, the release of IL-10 might in- 
duce  local  APCs  to  undergo  this  change  as  a  means  of 
preventing further APC function, or even as a prelude to the 
migration to the lymph nodes (16-18). By treating with anti- 
IL-10 mAb, we prevent these effects because the APCs do 
not become tolerogenic, but remain at the site for continued 
T cell activation.  Thus, skin 12-14 h after application of TNCB 
may function  similar  to UV-irradiated  skin  (44) in which 
IL-10 is released to inhibit CHS (40). Whatever the precise 
mechanism, however, we have made a strong case for an im- 
portant role for IL-10 in the natural regulation of the CHS 
response in vivo. 
We do not know if infiltrating cells (T cells, B cells, etc.) 
would play a role in production of IL-10 in sensitized skin. 
These cells  are known to make the cytokine (20, 36),  and 
could contribute to the enhanced production of the protein. 
However, we have observed that ear tissue from naive and 
immune mice have nearly identical levels of IL-10 protein and 
mRNA. Additionally,  treatment of mice with anti-IL-10 does 
not alter the number  of nlln  radiolabeled cells  that  traffic 
to the ear after application of TNCB (data not shown). Thus, 
it appears  that resident skin cells are the major source of IL- 
10 (19). 
An interesting component of these studies was the kinetics 
of IL-10 production.  The  cytokine was  upregulated  after 
TNCB application, but returned to normal levels by 20-24 h. 
The first  effects of IL-10 were observed at 8 h,  which was 
the time when the barrier to transfer of CHS was evident. 
Even though the level of IL-10 protein and mRNA returned 
to normal by 18-20 h, it appeared that the function of IL-10 
remained for several more hours. Even at 20 h it is not pos- 
sible to produce a CHS reaction unless the IL-10 was neu- 
tralized.  Perhaps the effect of IL-10 remains until skin cells 
(keratinocytes)  are replenished or the effect is inhibited by 
other factors.  Also suggested by our data is a role for IL-10 
in regulation  of its own production.  Treatment  with anti- 
IL-10 seemed to downmodulate the amount of IL-10 mRNA, 
suggesting  a feedback loop of IL-10 regulation.  However, 
this was difficult to determine, since we were not performing 
quantitative  RT-PCR.  We also detected less IL-10 in skin 
when mice were treated with anti-IL-10, however, this may 
be due to the large quantity of anti-IL-10 in tissue as a result 
of the  antibody treatment.  Recently it was observed that 
prolonged  treatment  with  anti-IL-10  resulted in increased 
production of TNF-c~ (35). TNF-ot is a cytokine critical to 
the induction and elicitation of CHS (7) and may be involved 
in regulating  IL-10 production.  It is also possible that  the 
prolongation of CHS by anti-IL-10 treatment is partially due 
to elevated levels of TNF-c~. A recent study (45) demonstrating 
that IL-10 inhibits production of TNF-ot is also supportive 
of this. Whatever the effect of IL-10 on its own production, 
IL-10 appears to be an important regulatory molecule in cell- 
mediated immune reactions in vivo. Besides a role in CHS 
reported here, IL-IO has been shown to be a pivotal cytokine 
in certain parasitic infections (34), where DTH plays an im- 
portant role in disease pathogenesis. Additionally, it has been 
shown to be a growth factor for B cells (20) and CTLs (25), 
and is an inhibitor of Thl cell function (32). This polyfunc- 
tional cytokine, therefore, has potential application  toward 
modulation  of T  cell function in vivo. 
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